Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

Similar articles for PubMed (Select 23676643)

2.

Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.

Breccia M, Palandri F, Iori AP, Colaci E, Latagliata R, Castagnetti F, Torelli GF, Usai S, Valle V, Martinelli G, Rosti G, Foà R, Baccarani M, Alimena G.

Leuk Res. 2010 Feb;34(2):143-7. doi: 10.1016/j.leukres.2009.04.036. Epub 2009 May 29.

PMID:
19481800
4.

[Sustained complete molecular remission after cessation of imatinib mesylate treatment in a patient with relapsed chronic myelogenous leukemia after allogeneic stem cell transplantation].

Igarashi T, Hayashi T, Yasui H, Ikeda H, Takahashi T, Ishida T, Shinomura Y.

Rinsho Ketsueki. 2012 Feb;53(2):215-8. Japanese.

PMID:
22450581
5.
6.
7.

Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment.

Simon W, Segel GB, Lichtman MA.

Blood Cells Mol Dis. 2006 Sep-Oct;37(2):116-24; discussion 125-7. Epub 2006 Aug 10.

PMID:
16904348
8.

Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.

Rogers G, Hoyle M, Thompson Coon J, Moxham T, Liu Z, Pitt M, Stein K.

Health Technol Assess. 2012;16(22):1-410. doi: 10.3310/hta16220. Review.

9.

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Müller MC, Ezzeddine R, Countouriotis AM, Kantarjian HM.

Leukemia. 2008 Jun;22(6):1200-6. doi: 10.1038/leu.2008.84. Epub 2008 Apr 10.

PMID:
18401416
10.

[Successful induction of complete cytogenetic response with high-dose imatinib mesylate and subsequent allogeneic stem cell transplantation for CML blastic crisis].

Sugiyama K, Usui N, Asai O, Saito T, Yano S, Okawa Y, Takahara S, Takei Y, Uno S, Dobashi N, Kobayashi M.

Rinsho Ketsueki. 2003 Jun;44(6):386-90. Japanese.

PMID:
12884817
12.

Characterization of cancer stem cells in chronic myeloid leukaemia.

Jørgensen HG, Holyoake TL.

Biochem Soc Trans. 2007 Nov;35(Pt 5):1347-51. Review.

PMID:
17956348
13.

Dasatinib maintenance therapy after allogeneic hematopoietic stem cell transplantation for an isolated central nervous system blast crisis in chronic myelogenous leukemia.

Nishimoto M, Nakamae H, Koh KR, Kosaka S, Matsumoto K, Morita K, Koh H, Nakane T, Ohsawa M, Hino M.

Acta Haematol. 2013;130(2):111-4. doi: 10.1159/000347158. Epub 2013 Mar 29.

PMID:
23548721
14.

Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic.

Klamova H, Faber E, Zackova D, Markova M, Voglova J, Cmunt E, Novakova L, Machova-Polakova K, Moravcova J, Dvorakova D, Michalova K, Brezinova J, Oltova A, Jarosova M, Cetkovsky P, Indrak K, Mayer J.

Neoplasma. 2010;57(4):355-9.

PMID:
20429627
15.

Clofarabine-based regimen as useful bridge therapy for allogeneic transplantation in myeloid blast crisis of Philadelphia-positive chronic myeloid leukemia resistant to imatinib and dasatinib.

Breccia M, Capria S, Iori AP, Foà R, Alimena G, Meloni G.

Acta Haematol. 2010;124(3):150-2. doi: 10.1159/000319630. Epub 2010 Oct 11. No abstract available.

PMID:
20938169
16.

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.

Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, Shah NP.

Blood. 2007 Mar 15;109(6):2303-9. Epub 2006 Nov 30. Erratum in: Blood. 2007 Sep 1;110(5):1438.

18.

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.

Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, Amadori S, de Souza CA, Lipton JH, Hochhaus A, Heim D, Larson RA, Branford S, Muller MC, Agarwal P, Gollerkeri A, Talpaz M.

Blood. 2007 May 15;109(10):4143-50. Epub 2007 Jan 30.

19.

Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia.

Li J, Xu G, Yu S, He L, Guo L.

J Int Med Res. 2011;39(2):337-47.

PMID:
21672337
20.

Successful prior treatment with dasatinib followed by stem cell transplantation in a patient with CML in blastic crisis with a BCR-ABL mutation.

Gotoh M, Tauchi T, Yoshizawa S, Kitahara T, Kiguchi T, Kimura Y, Ohyashiki K.

Int J Hematol. 2010 Jan;91(1):128-31. doi: 10.1007/s12185-009-0466-3. Epub 2010 Jan 5.

PMID:
20047099
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk